Evidence map›Paper›PMID 27698005›Full record

ArticleAmerican journal of epidemiology2016

Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.

Merlise A Clyde, Rachel Palmieri Weber, Edwin S Iversen, Elizabeth M Poole, Jennifer A Doherty, Marc T Goodman, Roberta B Ness, Harvey A Risch, Mary Anne Rossing, Kathryn L Terry and 31 more

Erratum issuedAbstract read
In one paragraph

Article in American journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Prospective Analysis of Circulating Biomarkers and Ovarian Cancer Risk in the UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  6. Article
  7. Prevention of Epithelial Ovarian Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  8. Observational
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Epidemiology of ovarian cancer: a review.Cancer biology & medicine · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors.

Merlise A Clyde
Rachel Palmieri Weber
Edwin S Iversen
Elizabeth M Poole
Jennifer A Doherty
Marc T Goodman
Roberta B Ness
Harvey A Risch
Mary Anne Rossing
Kathryn L Terry
Nicolas Wentzensen
Alice S Whittemore
Hoda Anton-Culver
Elisa V Bandera
Andrew Berchuck
Michael E Carney
Daniel W Cramer
Julie M Cunningham
Kara L Cushing-Haugen
Robert P Edwards
Brooke L Fridley
Ellen L Goode
Galina Lurie
Valerie McGuire
Francesmary Modugno
Kirsten B Moysich
Sara H Olson
Celeste Leigh Pearce
Malcolm C Pike
Joseph H Rothstein
Thomas A Sellers
Weiva Sieh
Daniel Stram
Pamela J Thompson
Robert A Vierkant
Kristine G Wicklund
Anna H Wu
Argyrios Ziogas
Shelley S Tworoger
Joellen M Schildkraut
, on behalf of the Ovarian Cancer Association Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
RPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6M
NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016359NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA072720NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01 CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA094069NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS U01 CA069417NCI NIH HHS U19 CA148112NCRR NIH HHS M01 RR000056
6 · The paper itself

Abstract

Previously developed models for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number of risk factors and have had low discriminatory power (area under the receiver operating characteristic curve (AUC) < 0.60). Because of this, we developed and internally validated a relative risk prediction model that incorporates 17 established epidemiologic risk factors and 17 genome-wide significant single nucleotide polymorphisms (SNPs) using data from 11 case-control studies in the United States (5,793 cases; 9,512 controls) from the Ovarian Cancer Association Consortium (data accrued from 1992 to 2010). We developed a hierarchical logistic regression model for predicting case-control status that included imputation of missing data. We randomly divided the data into an 80% training sample and used the remaining 20% for model evaluation. The AUC for the full model was 0.664. A reduced model without SNPs performed similarly (AUC = 0.649). Both models performed better than a baseline model that included age and study site only (AUC = 0.563). The best predictive power was obtained in the full model among women younger than 50 years of age (AUC = 0.714); however, the addition of SNPs increased the AUC the most for women older than 50 years of age (AUC = 0.638 vs. 0.616). Adapting this improved model to estimate absolute risk and evaluating it in prospective data sets is warranted.

Indexed as

Logistic ModelsAdultAgedArea Under CurveCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleGenetic LociGenetic Predisposition to DiseaseHumansMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsPolymorphism, Single NucleotideRisk AssessmentRisk Factorsgenetic risk polymorphismsmodel evaluationovarian cancerrisk model

Identifiers

PMID27698005
PMCPMC5065620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.